Profile data is unavailable for this security.
About the company
enGene Holdings Inc. is a holding company. The Company, through its subsidiary, enGene Inc., is engaged in developing non-viral gene therapies based on localized delivery of nucleic acid payloads to mucosal tissues. The Company’s proprietary dually derived chitosan (DDX) platform has a high degree of payload flexibility, including DNA and various forms of RNA with broad tissue and disease application. In preclinical animal and in vitro models, the Company’s DDX technology has been demonstrated to effectively induce expression of therapeutic genes following delivery to the lung, gastrointestinal tract, and urinary tract, and its lead product detalimogene voraplasmid (EG-70) is being developed for the treatment of bacillus calmette-guerin (BCG)-resistant non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS). EG-70 is a novel non-viral gene therapy designed to elicit a local immune response following the delivery to the bladder urothelium.
- Revenue in USD (TTM)0.00
- Net income in USD-106.80m
- Incorporated2023
- Employees33.00
- LocationenGene Holdings Inc4868 Rue Levy, Suite 220SAINT-LAURENT H4R 2P1CanadaCAN
- Phone+1 (514) 332-4888
- Websitehttps://engene.com/
Mergers & acquisitions
Acquired company | ENGN:NAQ since announced | Transaction value |
---|---|---|
enGene Inc | 34.88% | -- |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Arrivent Biopharma Inc | 0.00 | -69.33m | 592.84m | 40.00 | -- | -- | -- | -- | -2.17 | -2.17 | 0.00 | 4.73 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -87.86 | -- | -- | -- |
Stoke Therapeutics Inc | 7.85m | -108.53m | 598.34m | 110.00 | -- | 3.80 | -- | 76.27 | -2.42 | -2.42 | 0.1747 | 3.02 | 0.0322 | -- | 31.19 | 71,318.18 | -44.57 | -31.62 | -51.70 | -33.92 | -- | -- | -1,383.40 | -1,775.50 | -- | -- | 0.00 | -- | -29.22 | -- | -3.59 | -- | 11.56 | -- |
SNDL Inc | 664.96m | -122.99m | 599.13m | 2.52k | -- | 0.6816 | -- | 0.901 | -0.4721 | -0.4849 | 2.57 | 3.37 | 0.5995 | 5.29 | 36.58 | 264,294.20 | -11.34 | -24.44 | -12.28 | -27.94 | 24.17 | 22.49 | -18.92 | -62.17 | 2.69 | -9.29 | 0.1196 | -- | 27.63 | -- | 49.83 | -- | -- | -- |
Kyverna Therapeutics Inc | 0.00 | -60.37m | 603.61m | 96.00 | -- | -- | -- | -- | -1.39 | -1.39 | 0.00 | 1.14 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0368 | -- | -100.00 | -- | -108.93 | -- | -- | -- |
ORIC Pharmaceuticals Inc | 0.00 | -101.76m | 606.13m | 102.00 | -- | 1.84 | -- | -- | -1.81 | -1.81 | 0.00 | 4.87 | 0.00 | -- | -- | 0.00 | -35.25 | -33.92 | -37.18 | -35.77 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -12.99 | -- | 10.09 | -- |
Zymeworks Inc | 50.46m | -125.97m | 622.91m | 275.00 | -- | 1.43 | -- | 12.34 | -1.79 | -1.79 | 0.7086 | 6.15 | 0.0874 | -- | 1.03 | 185,529.40 | -21.82 | -22.58 | -24.45 | -26.90 | -- | -- | -249.63 | -91.17 | -- | -- | 0.0002 | -- | -81.57 | 7.47 | -195.44 | -- | 3.58 | -- |
Lyell Immunopharma Inc | 68.00k | -228.34m | 627.14m | 224.00 | -- | 1.04 | -- | 9,222.71 | -0.9057 | -0.9057 | 0.0003 | 2.37 | 0.00009 | -- | -- | 303.57 | -29.00 | -- | -30.21 | -- | -- | -- | -335,794.10 | -- | -- | -- | 0.00 | -- | -99.85 | -- | -28.13 | -- | -- | -- |
iTeos Therapeutics Inc | 12.60m | -112.64m | 627.24m | 157.00 | -- | 1.09 | -- | 49.80 | -3.15 | -3.15 | 0.3522 | 16.05 | 0.0177 | -- | 2.82 | 80,222.93 | -15.84 | 5.84 | -16.81 | 7.02 | -- | -- | -894.35 | 22.09 | -- | -- | 0.00 | 0.00 | -95.29 | -- | -216.54 | -- | 68.45 | -- |
enGene Holdings Inc | 0.00 | -106.80m | 627.56m | 33.00 | -- | 5.29 | -- | -- | -4.60 | -4.60 | 0.00 | 2.69 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -1.37 | 0.2653 | -- | -- | -- | -260.87 | -- | -- | -- |
Eyepoint Pharmaceuticals Inc | 50.02m | -78.92m | 629.70m | 121.00 | -- | 2.41 | -- | 12.59 | -1.83 | -1.83 | 1.17 | 5.01 | 0.2068 | 1.14 | 7.44 | 413,380.20 | -32.62 | -40.44 | -40.06 | -47.79 | 90.50 | 83.45 | -157.77 | -186.23 | 5.01 | -- | 0.00 | -- | 11.14 | -- | 30.77 | -- | -- | -- |
AnaptysBio Inc | 22.96m | -163.30m | 639.53m | 117.00 | -- | 13.38 | -- | 27.85 | -6.13 | -6.13 | 0.862 | 1.75 | 0.048 | -- | 5.33 | 196,256.40 | -34.11 | -18.08 | -36.72 | -18.96 | -- | -- | -711.18 | -269.21 | -- | -- | 0.00 | -- | 66.78 | 27.97 | -27.11 | -- | -5.36 | -- |
Sinovac Biotech Ltd | 448.27m | -105.90m | 639.90m | 3.04k | -- | -- | -- | 1.43 | -1.08 | -1.08 | 4.19 | 87.41 | 0.0323 | 1.13 | 0.9175 | 147,602.60 | -1.86 | 36.14 | -2.80 | 58.37 | 59.51 | 90.77 | -57.63 | 65.87 | 10.18 | -- | 0.0207 | -- | -69.97 | 14.31 | -198.16 | -- | 91.80 | -- |
Savara Inc | 0.00 | -54.70m | 643.21m | 37.00 | -- | 4.58 | -- | -- | -0.3424 | -0.3424 | 0.00 | 1.02 | 0.00 | -- | -- | 0.00 | -34.47 | -36.86 | -36.36 | -39.54 | -- | -- | -- | -102,587.50 | -- | -- | 0.158 | -- | -- | -- | -43.38 | -- | 15.91 | -- |
ProKidney Corp | 0.00 | -35.47m | 651.07m | 163.00 | -- | -- | -- | -- | -0.5683 | -0.5683 | 0.00 | -18.43 | 0.00 | -- | -- | 0.00 | -28.86 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0004 | -- | -- | -- | 67.17 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
BVF Partners LPas of 31 Dec 2023 | 2.25m | 5.19% |
Deep Track Capital LPas of 04 Apr 2024 | 2.25m | 5.19% |
Gritstone Asset Management LLCas of 30 Sep 2023 | 151.80k | 0.35% |
Polar Asset Management Partners, Inc.as of 31 Dec 2023 | 116.94k | 0.27% |
Tyrus Capital S.A.M.as of 30 Sep 2023 | 50.00k | 0.12% |
RBC Private Counsel (USA), Inc.as of 31 Dec 2023 | 37.85k | 0.09% |
Goldman Sachs & Co. LLC (Private Banking)as of 31 Dec 2023 | 37.45k | 0.09% |
Lumyna Investments Ltd.as of 30 Sep 2022 | 36.60k | 0.08% |
Citadel Securities LLCas of 31 Dec 2023 | 20.06k | 0.05% |
UBS Securities LLCas of 31 Dec 2023 | 1.94k | 0.00% |